These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …

Objective To investigate the effect of second‐generation antipsychotics on cognitive function
in patients diagnosed with schizophrenia or schizoaffective disorder. Method Multiple …

Context Psychotropic medication polypharmacy is common in psychiatric outpatient settings
and, in some patient groups, may have increased in recent years. Objective To examine …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Background Although clozapine is an effective option for treatment-resistant schizophrenia
(TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main …

One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

Context: Despite lacking evidence for its safety and efficacy, antipsychotic cotreatment is
common in schizophrenia. Objective: To evaluate therapeutic and adverse effects of …

Background: Although clozapine is the most effective medication for treatment refractory
schizophrenia, only 40% of people will meet response criteria. We therefore undertook a …